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There are no reliable nonictal biomarkers for epilepsy, electroencephalography (EEG)
or otherwise, but efforts to identify biomarkers that would predict the development of
epilepsy after a potential epileptogenic insult, diagnose the existence of epilepsy, or
assess the effects of antiseizure or antiepileptogenic interventions are relying heavily
on electrophysiology. The most promising EEG biomarkers to date are pathologic
high-frequency oscillations (pHFOs), brief EEG events in the range of 100 to 600 Hz,
which are believed to reflect summated action potentials from synchronously bursting
neurons. Studies of patients with epilepsy, and experimental animalmodels, have been
based primarily on direct brain recording, which makes pHFOs potentially useful for
localizing the epileptogenic zone for surgical resection, but application for other diag-
nostic and therapeutic purposes is limited. Consequently, recent efforts have involved
identification of HFOs recorded with scalp electrodes, and with magnetoencephalog-
raphy, which may reflect the same pathophysiologic mechanisms as pHFOs recorded
directly from the brain. The search is also on for other EEG changes that might serve
as epilepsy biomarkers, and candidates include arcuate rhythms, which may reflect
repetitive pHFOs, reduction in theta rhythm, which correlates with epileptogenesis in
several rodent models of epilepsy, and shortened sleep spindles that correlate with
ictogenesis.
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Epilepsy is characterized by the occurrence of epileptic
seizures, but not all seizures are epileptic, and not all epilep-
tic seizures are indicative of a chronic epilepsy disease.
Diagnosis can be confounded by the presence of psy-
chogenic or physiologic nonepileptic seizures, and two-
thirds of epileptic seizures are natural responses of a normal
brain to a transient insult and do not predict subsequent sei-
zure occurrence.1 A tentative diagnosis can be made from
electroclinical correlation when ictal events are captured on
electroencephalography (EEG), but this expensive, time-
consuming process is not practical to apply to the majority
of patients with suspected epilepsy. More useful diagnostic
biomarkers should be obtainable when patients are not hav-
ing seizures.
There are, however, no reliable nonictal biomarkers of
epilepsy, in the same sense that hemoglobin A1c is a bio-
marker of diabetes; therefore there is no test that definitively
warrants a diagnosis of epilepsy, or predicts, in people with
risk factors such as potential epileptogenic insults or genetic
predispositions, who will ultimately develop epilepsy.2–5
Since its initial clinical application in the mid-twentieth
century, the EEG has been relied upon to demonstrate non-
ictal epileptiform brain dysfunction with more diagnostic
validity in epilepsy than blood tests or neuroimaging.
Specifically, interictal EEG spikes can help make a diagno-
sis of epilepsy, when present, although EEG findings may
be normal in many people with epilepsy, and epileptiform
spikes can occasionally be seen in people without epilepsy.1
The patterns of interictal EEG spikes can also help to
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diagnose specific epilepsy syndromes, such as the general-
ized three-per-second spike-and-wave of absence epilepsy,
and the characteristic centrotemporal spike with a trans-
verse dipole seen in Rolandic epilepsy.1 Recordings of
interictal spikes are also used, invasively and noninvasively,
to localize the epileptogenic region for surgical resection,
and to predict who might be a good surgical candidate6;
however, decades of research have failed to identify any
other aspects of interictal EEG spikes that correlate with
either the severity of epilepsy, or the response to treatment,
with the singular exception of the absence epilepsies, where
the interictal spike waves are viewed as fragments of three-
per-second spike-and-wave ictal events.1
Need for Biomarkers
Biomarkers that reliably predict ictogenesis—that is,
identify the existence of brain areas that are likely to gener-
ate epileptic seizures—would obviously be useful for mak-
ing a diagnosis of epilepsy. This would be of particular
importance for patients who present with a single ictal
event. Because only 30% of patients presenting with a single
ictal event go on to develop epilepsy, in most cases treat-
ment is not instituted until a second seizure occurs, but the
next seizure carries a risk of morbidity and even mortality.
Consequently, the ability to distinguish between the first
seizure of epilepsy and a provoked seizure in a normal brain
due to a transient insult that would not be repeated, would
have tremendous therapeutic value. Patients could be trea-
ted immediately. Similarly, differential diagnosis between
psychogenic nonepileptic seizures and epilepsy could be
accomplished without the need for expensive and time-con-
suming video-EEGmonitoring.
Biomarkers that indicate the severity of epileptogenicity
—that is, the degree of likelihood of ictogenesis—could be
used to determine the effectiveness of therapeutic interven-
tions, whether pharmacologic or a device such as vagus
nerve stimulation (VNS), without the need to wait for
another seizure to occur. Elimination of the trial-and-error
approach to treatment of epilepsy would revolutionize the
management of epilepsy diseases. It would be possible, for
instance, to rapidly assess the effectiveness of different anti-
seizure drugs to find the one most likely to render the patient
seizure free or to determine that the patient is pharmacore-
sistant and needs to be considered for alternative treatments,
such as surgery. Biomarkers that indicate the severity of
epileptogenicity would also greatly facilitate clinical trials
of new antiseizure drugs.
There is currently no intervention that prevents the devel-
opment of epilepsy after a potential epileptogenic insult,
such as traumatic brain injury (TBI), intracranial infection,
or stroke. The primary reason for this is that it would be
prohibitively expensive to carry out a randomized clinical
trial to demonstrate the effectiveness of a putative
antiepileptogenic intervention. For instance, considering
prevention of posttraumatic epilepsy (PTE) following mild
to severe TBI, which occurs in only 15 to 20% of patients,
would require an extremely large subject population to
achieve statistically significant results; and because PTE
can take more than 10 years to develop, the trial would
need to last years, which would not be economically feasi-
ble.2 A reliable biomarker of epileptogenesis, one that
would predict with a high reliability those who will develop
PTE after TBI, would make it possible to enrich the subject
population for a clinical trial, and a biomarker of epilepto-
genicity that determines who will have epilepsy after the
preventive therapeutic intervention, without the need to
wait for a seizure to occur, would greatly shorten the trial
duration. There is, therefore, a concerted effort to identify
biomarkers of epileptogenesis that would make it possible
to ultimately identify antiepileptogenic interventions and
prevent epilepsy in at-risk patients. Once preventive
approaches become available, biomarkers of epileptogene-
sis will identify patients who would benefit from this
treatment.
Finally, biomarkers of ictogenesis and epileptogenesis
could make it possible to develop more cost-effective rapid
throughput screening models for discovery of antiseizure
and antiepileptogenic compounds.
pHFOs
In 1999, wideband EEG recordings demonstrated the
presence of brief high-frequency oscillations (HFOs) in the
range of 200–600 Hz, which were limited to epileptogenic
Key points
• There currently are no nonictal biomarkers that can be
used reliably to diagnose epilepsy, predict its develop-
ment, or evaluate the effects of antiseizure or
antiepileptogenic treatment
• Reliable epilepsy biomarkers would greatly facilitate
differential diagnosis, revolutionalize approaches to
treatment, and streamline new antiseizure and
antiepileptogenic drug discovery and validation
• To date, the best candidate for an epilepsy biomarker
is pHFOs, brief 100–600 Hz EEG events that are
recorded directly from the brain, and are believed to
reflect synchronously bursting neurons
• Basic research on pHFOs is elucidating fundamental
neuronal mechanisms of epileptogenesis and ictogen-
esis
• General clinical application of biomarkers for diagno-
sis and treatment, however, requires noninvasive iden-
tification; therefore recent efforts are aimed at
recording pHFOs with scalp EEG and magnetoen-
cephalography (MEG), and finding other possible
EEG biomarkers




tissue in patients with mesial temporal lobe epilepsy and
animal models of this condition7–9 (Fig. 1). Since then,
attention has been focused on recording pathologic HFOs
(pHFOs), not only as indicators of the epileptogenic region
for surgical resection, but also as potential biomarkers of
epileptogenesis (the development of epilepsy) and of ictoge-
nesis (the diagnosis of epilepsy).
The normal hippocampus generates HFOs in the range of
80–200 Hz, termed ripples, reflecting summated inhibitory
post-synaptic potentials (IPSPs), which function to support
information transfer by synchronizing activity over broad
areas. pHFOs were originally described in the frequency
range of 200–600 Hz and were termed fast ripples. Subse-
quently, it was demonstrated that although normal HFOs
reflect summated IPSPs,10 pHFOs represent summated
action potentials from synchronously bursting neurons, the
hallmark of an epileptogenic region.11,12 It soon became
apparent, however, that frequency alone did not distinguish
pathologic from normal events, because the dentate gyrus,
which normally does not generate ripples, exhibits ripple
frequency HFOs in epileptic rats. Ripple frequency oscilla-
tions, therefore, could be either normal or pathologic, and
there is no easy way to distinguish between these 2 types of
ripples on EEG.11,12 Furthermore, HFOs in the fast ripple
range can occur in primary areas of neocortex.11,12
In addition to a large literature associating the presence of
pHFOs with epileptogenicity in animal models of epilepsy,
and the fact that removal of pHFO-generating brain areas is
associated with a seizure-free surgical outcome in
patients,2,3 clinical studies indicate that pHFOs are
biomarkers of epileptogenicity regardless of lesion type,13
and measure the degree of epileptogenicity.14 In the latter
study, whereas interictal spikes increase postictally when
seizure threshold is high, pHFOs do not increase, but they
do increase after medication reduction when seizure thresh-
old is reduced, demonstrating that pHFOs more reliably
indicate the degree of epileptogenicity than interictal
spikes.14 Animal studies have demonstrated that pHFOs
occur early after 2 epileptogenic insults, intrahippocampal
kainic acid injection,15 and fluid percussion TBI,16 and reli-
ably predict animals that will go on to have spontaneous sei-
zures. pHFOs have yet to be confirmed as reliable
biomarkers of epileptogenesis in patients.
Although pHFOs currently are the most promising epi-
lepsy biomarkers for clinical application, a major limitation
is that most of the animal and human work that has been
done to demonstrate their reliability in specific situations
requires direct brain recording. Initial studies were carried
out with microelectrodes best capable of identifying activity
in local microcircuits,7,8,17 but more recent work has clearly
demonstrated the ability of clinical depth and subdural elec-
trodes to identify both ripple and fast ripple frequency
HFOs.18–21 Of interest, with the larger clinical electrodes,
ripple frequency HFOs have almost the same ability to
localize the epileptogenic region as fast ripple frequency
HFOs, perhaps due to the more localized dipoles of patho-
logic events, compared to the more distributed dipoles of
normal events.12
Figure 1.
Low and high frequency ripples in human entorhinal cortex. A,
Power spectrum of electrical activity recorded from microelec-
trode 2. Recording bandwidth: 0.1–10,000 Hz.; peaks at 96 and
284 Hz. B–D, Examples of the unit activity, ripples and fast ripples
recorded from the same file with 2 electrodes within entorhinal
cortex. E–G, Averages of events (the number is indicated in paren-
theses). Due to similarities of amplitudes, the events were selected
into different files by visual estimation. Single unit activity was
recorded only from microelectrode 2; note that ripples are in
phase on both electrodes and the fast ripples are out of phase.
From Bragin et al7, with permission.
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Given that pHFOs have largely been identified by direct
brain recording, the majority of studies confirming their
reliability as a biomarker of epilepsy have been limited to
identification of the epileptogenic region for surgery, which
is discussed in detail in the next chapter (J. Wu this issue).
Various aspects of HFOs, such as their occurrence on spikes
and relationship to slow waves, have been used to distin-
guish pHFOs from normal HFOs, and novel approaches are
utilized to identify false HFOs, and to improve automatic
detection.22–27 Most importantly, however, for the future
clinical application of pHFOs to diagnosis and treatment,
and to predict patients at risk for epilepsy, work is being
done to identify pHFOs noninvasively. Several studies have
now reported the ability to record activity in the HFO fre-
quency range from scalp electrodes,28–30 but it is unclear
whether these events are the same as those recorded directly
from the brain. Others have reported the ability to record
HFOs with magnetoencephalography (MEG).31,32 It is con-
ceivable that interictal spikes associated with pHFOs will
have a metabolic profile on functional magnetic resonance
imaging (fMRI) that distinguishes them from interictal
spikes without pHFOs, and some data are accumulating sug-
gesting that fMRI may help to identify pHFOs noninva-
sively.33 Although we are close to accepting that pHFOs,
recorded during chronic invasive monitoring, and intraoper-
atively, delineate the epileptogenic region for surgery, the
clinical application of these EEG events for seizure diagno-
sis, treatment, and prediction, in the routine population of
people with epilepsy, remains a hope for the future.
Neuronal Mechanisms of Normal
and Pathologic HFOs
Several reviews have been published on mechanisms of
normal and pathologic HFOs.34–37 Here we summarize
widely accepted views. Hippocampal ripples are summated
IPSPs and reflect the most synchronous physiologic patterns
in the mammalian brain.10,35 They are associated with
increased discharges of both pyramidal cells and interneu-
rons.38,39 Under normal conditions the interneuronal net-
work maintains synchrony of discharges of principal cells at
a level below that required for the formation of population
spikes. We can make a similar assumption for the mecha-
nism of generation and function of physiologic HFO genera-
tion in other brain areas outside of hippocampus.40–46
pHFOs have a different mechanism of generation. They
reflect bursts of population spikes47–52 in local clusters of
principal neurons imbedded in normal tissue.49 A separation
of normal and pHFOs based on frequency, as initially was
proposed,7,8 is not correct. In rats with epilepsy, abnormal
burst of population spikes may occur in the ripple frequency
band50 and some pHFOs are a mixture of oscillations in the
ripple and fast ripple frequency band,53 whereas in primary
neocortical areas oscillations in the fast ripple frequency
range can be physiologic.11
The mechanisms generating bursts of population spikes
are not known, but studies suggest morphologic alterations
associated with lesions are involved in their generation.37–
54 In rat models of temporal lobe epilepsy, pHFOs occur in
hippocampal areas with mossy fiber sprouting,8,55 and
pHFO power increases as tissue cell density decreases.56
Studies in patients with hippocampal sclerosis indicate
higher rates of pHFO occurrence and a greater density of
pHFO-generating sites correspond with the severity of cell
loss and synaptic reorganization.57,58 However, the struc-
tural disturbances involved in the generation of pHFOs are
not consistent,59,60 and some morphologic alterations
appear more epileptogenic than others.13,61 Microcircuit
alterations, such as deficits in astrocyte-mediated gluta-
mate and c-aminobutyric acid (GABA) regulation62–64
could contribute to neuronal hyperexcitability found in
epileptogenic tissue.65,66 Computer models that combine
reduced inhibition, increased “synaptic noise,” which could
derive from abnormal neuronal spike firing, and synaptic
reorganization can generate pHFOs.67
Mechanism of Ictogenesis
A critical aspect of pHFO pathophysiology is that these
unique EEG events, as recorded with microelectrodes in
hippocampus, are not generated diffusely in a homoge-
neous fashion throughout the structure, but, rather, by
small clusters of presumably pathologically interconnected
neurons (PIN clusters) distributed widely within more nor-
mal networks of nonepileptogenic neurons.68 These PIN
clusters are spatially stable over time,68 but with reduction
in local tonic inhibitory influences, they can increase in
size.50 This presents a putative mechanism for ictogene-
sis11: as a result of a variety of influences that can reduce
inhibitory tone within the hippocampus, PIN clusters can
increase in size, coalesce, and synchronize until a critical
mass is reached and epileptiform discharges are propa-
gated. Animal studies have, indeed, shown that pHFO
bursts increase in amplitude and duration prior to ictal
events, consistent with this hypothesis.69 Furthermore, in a
rat model of mesial temporal lobe epilepsy, seizure fre-
quency is positively correlated with the density of PIN
clusters, which is also consistent with this hypothesis.68
Consequently, pHFOs are of interest not only because they
are likely biomarkers of a variety of aspects of epilepsy,
but because the underlying mechanisms of their generation
will likely provide insight into fundamental neuronal
mechanisms of epileptogenesis and ictogenesis, and novel
targets for antiseizure and antiepileptogenic interventions.
Other Potential EEG
Biomarkers
Reports from the animal literature have suggested 3
additional changes in routine noninvasive EEG that




appear to correlate with epileptogenesis or ictogenesis.
In the fluid percussion TBI rat model, arcuate-shaped
discharges can be recorded with skull screws adjacent
to the injury, which appear to predict which animals
will eventually develop PTE.16 Microelectrode record-
ings demonstrate that these arcuate events reflect the
presence of pHFOs (Fig. 2). In another study of epilep-
togenesis in 5 different models of postinjury epilepsy,
there was a consistent reduction in theta activity over
time, following injury, which predicted the later devel-
opment of epilepsy with a sensitivity and specificity of
90%.70 Finally, in the rat fluid percussion model of
PTE following TBI, 93% of spontaneous seizures
occurred during the transition from stage III to rapid
eye movement sleep, and a reduction in spindle duration
during this time was a specific and sensitive noninva-
sive biomarker of ictogenesis.71 Scalp EEG is a readily
available clinical diagnostic test. If any of these obser-
vations in animal models of epilepsy correlate with sim-
ilar changes in patients, there is a reasonable possibility
that specific EEG changes could eventually provide reli-
able nonictal biomarkers for a variety of aspects of
epileptogenesis and epileptogenicity that could pro-
foundly influence diagnosis, treatment, prediction, and
prevention.
Conclusions
To date, EEG has yielded the most promising nonictal
biomarkers of epileptogenesis and epileptogenicity, chief
among these being pHFOs. For biomarkers to be clinically
useful in diagnosing epilepsy, identifying persons at risk of
developing epilepsy after a potential epileptogenic insult or
with genetic predisposition, or assessing the effects of anti-
seizure treatment or antiepileptogenic intervention, it will
be necessary to identify them noninvasively.
Efforts, therefore, are now focused on identifying pHFOs
with scalp EEG and MEG, as well as validating other poten-
tial EEG biomarkers such as arcuate patterns that reflect
repetitive pHFOs, changes in theta rhythm, and shortened
sleep spindles.
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